Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP7 | P09237 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP12 | P39900 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | MME | P08473 | 3/20 | 0.63 |
| ▸ | ACE | P12821 | 3/20 | 0.62 |
| ▸ | CPA1 | P15085 | 1/20 | 0.62 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864709 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL29519583 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL28860411 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL27517670 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| Water SCHEMBL29655482 | 0.99 | LTA4H (0.62) | LTA4HMMP2MMP7MMP9MMP12 | |
| Leu-Leu SCHEMBL10364547 | 0.97 | LTA4H (0.68) | LTA4HMMP2MMP7MMP9MMP12 | |
| Urea SCHEMBL28230423 | 0.97 | LTA4H (0.61) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30051537 | 0.97 | LTA4H (0.61) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30050978 | 0.96 | LTA4H (0.63) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30053218 | 0.95 | LTA4H (0.58) | LTA4HMMP2MMP7MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388590-B | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LFAGA, RDWPEGR, DWPEGR and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-09-24 | — | — | CN | claimed |
| EP-4422686-A1 | MAGNETOSTRICTIVE PIEZOELECTRIC NANOASSEMBLY AS CANCER CHEMOTHERAPEUTIC | Grant Demartino Industries LLC (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118388590-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LFAGA, RDWPEGR, DWPEGR and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-07-26 | — | — | CN | claimed |
| CN-117567562-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-02-20 | — | — | CN | claimed |
| CN-116063386-A | Deer antler plate immunocompetent peptide, and preparation method and application thereof | 吉林农业大学 | 2023-05-05 | — | — | CN | claimed |
| WO-2023073560-A1 | MAGNETOSTRICTIVE PIEZOELECTRIC NANOASSEMBLY AS CANCER CHEMOTHERAPEUTIC | GRANT DEMARTINO INDUSTRIES LLC (US) | 2023-05-04 | — | — | WO | claimed |
| CN-115873092-A | Antibacterial polypeptide from banded snake, preparation method and application thereof | 中国药科大学 | 2023-03-31 | — | — | CN | claimed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | claimed |
| WO-2022148418-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF BEING DELIVERED BY METERED DOSE INHALER | 江苏恒瑞医药股份有限公司 | 2022-07-14 | — | — | WO | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| CN-1265673-A | Dipeptide compounds for inhibiting leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| US-20260132136-A1 | Pyrazolo[5,1-f][1,2,4]triazin-4-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| EP-4735882-A1 | BAT-BASED METHOD FOR DETERMINING THE PREVALENCE AND/OR SEVERITY OF AN ALLERGY IN AN INDIVIDUAL AND KITS THEREFORE | Forschungszentrum Borstel, Leibniz Lungenzentrum (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260109682-A1 | NOVEL COMPOUNDS AND THE USE FOR PROMOTING HAIR GROWTH OR INHIBITING INFLAMMATORY DISORDERS THEREOF | CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2026-04-23 | — | — | US | disclosed |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| US-12583929-B2 | Method of treating acute respiratory distress syndrome | CSL Innovation Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4709423-A1 | NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2026-03-18 | — | — | EP | disclosed |
| WO-2026046899-A1 | PYRAZOLO[5,1-f][1,2,4]TRIAZIN-4-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-03-05 | — | — | WO | disclosed |
| US-20260062478-A1 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | CEPHALON LLC | 2026-03-05 | — | — | US | disclosed |
| US-20260035452-A1 | NOVEL INTERLEUKIN-17A (IL-17A)-DERIVED PEPTIDE AND NEUTRALIZING ANTIBODY (AB17-IPL-1) | THE UNIVERSITY OF BIRMINGHAM (GB) | 2026-02-05 | — | — | US | disclosed |
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368958-A1 | CAR-EXPRESSING PLURIPOTENT STEM CELL-DERIVED NEUTROPHILS LOADED WITH DRUG NANOPARTICLES AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | disclosed |
| CN-120908341-A | AAGN disease metabolism marker, kit and application thereof | 中南大学湘雅医院 | 2025-11-07 | — | — | CN | disclosed |
| US-12428461-B2 | Treating cancer with a conjugate comprising an IL-2 moiety | Ascendis Pharma Oncology Division A/S (DK) | 2025-09-30 | — | — | US | disclosed |
| US-12384841-B2 | Anti-PAR-2 antibodies and methods of use thereof | CEPHALON LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-12365709-B2 | Immunomodulatory peptide | INSTITUT NATIONAL UNIVERSITAIRE JEAN-FRANCOIS CHAMPOLLION (FR) | 2025-07-22 | — | — | US | disclosed |
| EP-4565609-A1 | NOVEL INTERLEUKIN-17A (IL-17A)-DERIVED PEPTIDE AND NEUTRALIZING ANTIBODY (AB17-IPL-1) | The University Of Birmingham (GB) | 2025-06-11 | — | — | EP | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-3906065-B1 | PRR AGONIST FOR USE IN THE TREATMENT OF CANCER | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2025-04-30 | — | — | EP | disclosed |
| CN-119874816-A | Tartary buckwheat protein source hypolipidemic peptide and application thereof | 华南农业大学 | 2025-04-25 | — | — | CN | disclosed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025053427-A1 | MICROFLUIDIC DEVICE CAPABLE OF SIMULATING TISSUE OR ORGANS USING CELLS | 한국화학연구원 | 2025-03-13 | — | — | WO | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119421946-A | Drug nanoparticle-loaded pluripotent stem cell-derived neutrophils expressing CAR and uses thereof | 普渡研究基金会 | 2025-02-11 | — | — | CN | disclosed |
| CN-119390840-A | Antibodies that bind to ILT4 | 戊瑞治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025003040-A1 | BAT-BASED METHOD FOR DETERMINING THE PREVALENCE AND/OR SEVERITY OF AN ALLERGY IN AN INDIVIDUAL AND KITS THEREFORE | FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM (DE) | 2025-01-02 | — | — | WO | disclosed |
| EP-4484951-A1 | BAT-BASED METHOD FOR DETERMINING THE PREVALENCE AND/OR SEVERITY OF AN ALLERGY IN AN INDIVIDUAL AND KITS THEREFORE | Forschungszentrum Borstel, Leibniz Lungenzentrum (DE) | 2025-01-01 | — | — | EP | disclosed |
| EP-4200018-B1 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | CEPHALON LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024231442-A1 | NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2024-11-14 | — | — | WO | disclosed |
| US-20240366762-A1 | CHIMERIC FC-ALPHA RECEPTORS AND USES THEREOF | Sanquin IP B.V. (NL) | 2024-11-07 | — | — | US | disclosed |
| US-20240368280-A1 | ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2024-11-07 | — | — | US | disclosed |
| US-12136284-B2 | Label-free hematology and pathology analysis using deep-ultraviolet microscopy | GEORGIA TECH RESEARCH CORPORATION (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240358711-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | IMMUNYX PHARMA LTD. (IL) | 2024-10-31 | — | — | US | disclosed |
| EP-4454659-A2 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | Cephalon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118745209-A | Stable antibacterial peptide in blood plasma and preparation method and application thereof | 国家纳米科学中心 | 2024-10-08 | — | — | CN | disclosed |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT (DE) | 2024-10-03 | — | — | US | disclosed |
| CN-118388590-B | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LFAGA, RDWPEGR, DWPEGR and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024180018-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| US-12077607-B2 | Functional and therapeutic effects of PAR4 cleavage by cathepsin G | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| US-20240268402-A1 | Methods, Devices and Compositions for Preserving Human Milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| CN-118388590-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LFAGA, RDWPEGR, DWPEGR and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-07-26 | — | — | CN | disclosed |
| US-20240248074-A1 | METHOD AND SYSTEM FOR SINGLE-CELL BIOPHYSICAL PROFILING USING A MICROFLUIDIC DEVICE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-25 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4396229-A1 | ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-12031976-B2 | Screening method for therapeutic substance for preventing or treating bronchopulmonary dysplasia (BPD) | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2024-07-09 | — | — | US | disclosed |
| CN-116761821-B | Anti-PAR-2 antibodies and methods of use thereof | 赛福伦有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240183863-A1 | ELISA Assay for Measuring Function of Properdin and Kits for Conducting ELISA Assays using Anti-properdin Antibodies | THE UNIVERSITY OF TOLEDO (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| CN-117567562-B | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-06-04 | — | — | CN | disclosed |
| CN-118043352-A | Anti-CECAM antibody with reduced side effects | 德国癌症研究中心公共法律基金会 | 2024-05-14 | — | — | CN | disclosed |
| US-20240150457-A1 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD. (AU) | 2024-05-09 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117886882-A | Screening and application of walnut pancreatic lipase inhibitory peptide | 云南农业大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347128-A2 | METHOD AND SYSTEM FOR SINGLE-CELL BIOPHYSICAL PROFILING USING A MICROFLUIDIC DEVICE | Nanyang Technological University (SG) | 2024-04-10 | — | — | EP | disclosed |
| CN-112961212-B | ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 河南省农业科学院农副产品加工研究中心 | 2024-03-29 | — | — | CN | disclosed |
| CN-112961212-B | ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 河南省农业科学院农副产品加工研究中心 | 2024-03-29 | — | — | CN | disclosed |
| US-20240101618-A1 | IMMUNOMODULATORY PEPTIDE | INSTITUT NATIONAL UNIVERSITAIRE JEAN-FRANCOIS CHAMPOLLION (FR) | 2024-03-28 | — | — | US | disclosed |
| CN-117567562-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024028436-A1 | NOVEL INTERLEUKIN-17A (IL-17A)-DERIVED PEPTIDE AND NEUTRALIZING ANTIBODY (AB17-IPL-1) | THE UNIVERSITY OF BIRMINGHAM (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117480175-A | Fluorescent probe | 东北泰克诺亚奇股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117480178-A | Chimeric FC-alpha receptors and uses thereof | 桑昆专利有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-11879001-B2 | Conjugate comprising an IL-2 moiety | Ascendis Pharma Oncology Division A/S (DK) | 2024-01-23 | — | — | US | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| US-11845708-B2 | Method for photocleavage of amide bonds | NANJING TECH UNIVERSITY (CN) | 2023-12-19 | — | — | US | disclosed |
| EP-4277663-A1 | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD BRAIN BARRIER | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230355815-A1 | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD BRAIN BARRIER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-11-09 | — | — | US | disclosed |
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-10-26 | — | — | US | disclosed |
| US-11794184-B2 | Three-dimensional (3D) hydrogel patterning in microfluidic vascular models | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-10-24 | — | — | US | disclosed |
| EP-4259776-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | Purdue Research Foundation (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116761821-A | anti-PAR-2 antibodies and methods of use thereof | 赛福伦有限责任公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11753440-B2 | Methods for the synthesis of arginine-containing peptides | DSM IP ASSETS B.V. (NL) | 2023-09-12 | — | — | US | disclosed |
| US-11753452-B2 | Immunomodulatory peptide | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 2023-09-12 | — | — | US | disclosed |
| US-20230272087-A1 | METHOD OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL LIMITED AND CSL INNOVATION PTY LTD (AU) | 2023-08-31 | — | — | US | disclosed |
| CN-115047120-B | Method for analyzing and detecting dansyl chloride derivative of dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11725052-B2 | Anti-PAR-2 antibodies and methods of use thereof | CEPHALON LLC (US) | 2023-08-15 | — | — | US | disclosed |
| CN-116601290-A | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use | 普渡研究基金会 | 2023-08-15 | — | — | CN | disclosed |
| CN-116507633-A | Glycosylated IL-2 proteins and uses thereof | 阿森迪斯药物肿瘤股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4204439-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-20230201355-A1 | IL-2 SEQUENCES AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-06-29 | — | — | US | disclosed |
| US-20230190723-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230174605-A1 | IL-2 SEQUENCES AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-06-08 | — | — | US | disclosed |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
| US-20230158031-A1 | Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-25 | — | — | US | disclosed |
| CN-116133676-A | IL-2 sequences and uses thereof | 阿森迪斯药物肿瘤股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116063386-A | Deer antler plate immunocompetent peptide, and preparation method and application thereof | 吉林农业大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063386-A | Deer antler plate immunocompetent peptide, and preparation method and application thereof | 吉林农业大学 | 2023-05-05 | — | — | CN | disclosed |
| US-20230126796-A1 | FUNCTIONAL AND THERAPEUTIC EFFECTS OF PAR4 CLEAVAGE BY CATHEPSIN G | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| EP-4161956-A1 | IL-2 SEQUENCES AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-04-12 | — | — | EP | disclosed |
| CN-110996950-B | Piperidinone formyl peptide 2 receptor agonists and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115873092-A | Antibacterial polypeptide from banded snake, preparation method and application thereof | 中国药科大学 | 2023-03-31 | — | — | CN | disclosed |
| US-20230102309-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DE) | 2023-03-30 | — | — | US | disclosed |
| EP-3928100-B1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LTD (GB) | 2023-03-22 | — | — | EP | disclosed |
| CN-115785215-A | Mussel peptide and preparation method and application thereof | 青岛琛蓝生物科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023031366-A1 | ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-03-09 | — | — | WO | disclosed |
| EP-4138836-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND OTHER DISORDERS INVOLVING CYTOKINE STORM USING BTK INHIBITORS | Principia Biopharma Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-110997652-B | Piperidinone formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-4130263-A1 | COMPOUND AND METHOD FOR A SPECIFIC TARGETING OF THE HAX1 GENE | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023007499-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | IMMUNYX PHARMA LTD. (IL) | 2023-02-02 | — | — | WO | disclosed |
| US-20230028447-A1 | SCREENING METHOD FOR THERAPEUTIC SUBSTANCE FOR PREVENTING OR TREATING BRONCHOPULMONARY DYSPLASIA (BPD) | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-01-26 | — | — | US | disclosed |
| EP-4106757-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | Mereo Biopharma 4 Limited (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
| CN-115443136-A | Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using BTK inhibitors | 普林斯匹亚生物制药公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022250617-A2 | METHOD AND SYSTEM FOR SINGLE-CELL BIOPHYSICAL PROFILING USING A MICROFLUIDIC DEVICE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-12-01 | — | — | WO | disclosed |
| US-20220380443-A1 | TARGETING NAPA-LINKED PEPTIDOGLYCAN FOR TREATING LYME DISEASE | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220366709-A1 | Label-Free Hematology and Pathology Analysis Using Deep-Ultraviolet Microscopy | NATIONAL SCIENCE FOUNDATION | 2022-11-17 | — | — | US | disclosed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20220305136-A1 | ANTI-CTLA4 CONJUGATES | ASCENDIS PHARMA GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220289665-A1 | METHOD FOR PHOTOCLEAVAGE OF AMIDE BONDS | NANJING TECH UNIVERSITY (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-4042224-A1 | LABEL-FREE HEMATOLOGY AND HISTOPATHOLOGY ANALYSIS USING DEEP-ULTRAVIOLET MICROSCOPY | Georgia Tech Research Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022155499-A1 | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD BRAIN BARRIER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022148418-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF BEING DELIVERED BY METERED DOSE INHALER | 江苏恒瑞医药股份有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022125850-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022126004-A1 | HYDROGELS ENCAPSULATING ENZYMES THAT DEPHOSPHORYLATE ADENOSINE AND USES IN MEDICAL APPLICATIONS | EMORY UNIVERSITY (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3986478-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| US-20220120760-A1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| WO-2022043493-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | WO | disclosed |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220056125-A1 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | ABCELLERA BIOLOGICS INC. (CA) | 2022-02-24 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| EP-3954991-A2 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | Laboratory Corporation of America Holdings (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3151665-B1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORP AMERICA HOLDINGS (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3546940-B1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3129909-B1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200284805-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-09-10 | — | — | US | disclosed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10634686-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200103417-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| EP-3546940-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| CN-106255885-B | Monitoring inflammatory states | 莫洛迪克有限公司 | 2019-09-10 | — | — | CN | disclosed |
| US-10267777-B2 | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | METABOLON, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| CN-109416357-A | For detecting the equipment, system and method for the analyte in the body fluid sample for including multiple cells | 皇家飞利浦有限公司 | 2019-03-01 | — | — | CN | disclosed |
| US-20180348199-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3410115-A1 | TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180314790-A1 | System, Method and Apparatus for Determining the Effect of Genetic Variants | METABOLON, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-2997366-B1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-10041932-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2018-08-07 | — | — | US | disclosed |
| CN-108047304-A | - 7 selective depressant of metalloproteinases and its preparation method and application | 延边大学 | 2018-05-18 | — | — | CN | disclosed |
| CN-107727577-A | Determine container | 浜松光子学株式会社 | 2018-02-23 | — | — | CN | disclosed |
| US-20180003721-A1 | Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients | JOSLIN DIABETES CENTER (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | disclosed |
| US-20170276669-A1 | PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-09-28 | — | — | US | disclosed |
| EP-3215633-A1 | SYSTEM, METHOD AND APPARATUS FOR DETERMINING THE EFFECT OF GENETIC VARIANTS | Metabolon, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| CN-104677810-B | The detection kit and its application method of Basohil activation | 广东医学院附属医院 | 2017-08-22 | — | — | CN | disclosed |
| CN-106588965-A | Urea peptidomimetic boric acid compound as well as pharmaceutical composition, preparation method and application thereof | 北京大学 | 2017-04-26 | — | — | CN | disclosed |
| US-20170089872-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| CN-104597153-B | Assay method of ligusticum wallichii fingerprint | 上海现代中医药股份有限公司 | 2017-02-01 | — | — | CN | disclosed |
| CN-104569268-B | A kind of assay method of Rhizoma Chuanxiong volatile oil clathrate finger printing | 上海现代中医药股份有限公司 | 2016-11-02 | — | — | CN | disclosed |
| US-20160231330-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2016073547-A1 | SYSTEM, METHOD AND APPARATUS FOR DETERMINING THE EFFECT OF GENETIC VARIANTS | METABOLON, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160116486-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160091481-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2016-03-31 | — | — | US | disclosed |
| US-20160091480-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2016-03-31 | — | — | US | disclosed |
| EP-2997366-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9176113-B1 | Methods and systems for determining autism spectrum disorder risk | SYNAPDX CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150293072-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2015-10-15 | — | — | US | disclosed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150294081-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2015-10-15 | — | — | US | disclosed |
| CN-104597153-A | Assay method of ligusticum wallichii fingerprint | SHANGHAI SUNDISE TRADITIONAL CHINESE MEDICINE CO LTD | 2015-05-06 | — | — | CN | disclosed |
| CN-104569268-A | Testing method of ligusticum chuanxiong hort volatile oil inclusion compound fingerprint spectrum | SHANGHAI SUNDISE TRADITIONAL CHINESE MEDICINE CO LTD | 2015-04-29 | — | — | CN | disclosed |
| WO-2015042602-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150004261-A1 | Rhizoma Arisaematis Extracts and Uses Thereof for Wound-Healing Effects | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-01-01 | — | — | US | disclosed |
| US-20150004261-A1 | Rhizoma Arisaematis Extracts and Uses Thereof for Wound-Healing Effects | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-01-01 | — | — | US | disclosed |
| WO-2014186311-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-104053447-A | Arisaema consanguineum extract and its use for wound healing | UNIV HONG KONG SCIENCE & TECHN | 2014-09-17 | — | — | CN | disclosed |
| US-20140156573-A1 | METHODS FOR GENERATING PREDICTIVE MODELS FOR EPITHELIAL OVARIAN CANCER AND METHODS FOR IDENTIFYING EOC | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8443799-B2 | Dry powder inhalation system for transpulmonary administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013056514-A1 | RHIZOMA ARISAEMATIS EXTRACTS AND USES THEREOF FOR WOUND-HEALING EFFECTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2013-04-25 | — | — | WO | disclosed |
| US-8333193-B2 | Dry powder inhalation system for transpulmonary administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-7735485-B2 | Dry powder inhalation system for transpulmonary administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090126732-A1 | DRY POWDER INHALATION SYSTEM FOR TRANSPULMONARY ADMINISTRATION | OTSUKA PHARMACEUTICAL CO., LTD. | 2009-05-21 | — | — | US | disclosed |
| US-20090095293-A1 | DRY POWDER INHALATION SYSTEM FOR TRANSPULMONARY ADMINISTRATION | OTSUKA PHARMACEUTICAL CO., LTD. | 2009-04-16 | — | — | US | disclosed |
| US-7448379-B2 | Inhalation system for transpulmonary administration according to which a freeze-dried composition provided housed in a vessel can be prepared into a form suitable for transpulmonary administration by being made into fine particles at the time of use, and administered by inhalation as is | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| EP-1863513-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | The University of North Carolina at Chapel Hill (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070065371-A2 | Novel Dry Powder Inhalation System For Transpulmonary Administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-10-26 | — | — | US | disclosed |
| WO-2006113236-A2 | NOVEL CHEMICAL INHIBITORS OF NEUTROPHIL ACTIVATION THROUGH THE SAC-DEPENDENT PATHWAY | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1402913-B1 | DRY POWDER INHALATION SYSTEM FOR TRANSPULMONARY ADMINISTRATION, METHOD OF MANUFACTURING A DRY POWDERED PREPARATION, AND USE OF A FREEZE DRIED COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2006-08-23 | — | — | EP | disclosed |
| EP-1688133-A1 | Freeze-dried composition for transpulmonary administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1688134-A2 | Dry powder inhaler for transpulmonary administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060073105-A1 | Novel dry powder inhalation system for transpulmonary administration | YAMASHITA CHIKAMASA | 2006-04-06 | — | — | US | disclosed |
| EP-1579855-A1 | NOVEL DRY POWDER INHALATION SYSTEM FOR TRANSPULMONARY ADMINISTRATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-09-28 | — | — | EP | disclosed |
| EP-1402913-A1 | DRY POWDER INHALATION SYSTEM FOR TRANSPULMONARY ADMINISTRATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030101995-A1 | Dry powder inhalation system for transpulmonary administration | OTSUKA PHARMACEUTICAL CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| EP-1028743-A4 | TREATMENT AND DIAGNOSIS OF INFERTILITY USING TGF$g(b) OR ACTIVIN | LUMINIS PTY LTD (AU) | 2002-06-12 | — | — | EP | disclosed |
| EP-1038533-A1 | MEDICINAL COMPOSITIONS FOR TREATING IMMUNODEFICIENCY DISEASES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-09-27 | — | — | EP | disclosed |
| CN-1265673-A | Dipeptide compounds for inhibiting leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| EP-1028743-A1 | TREATMENT AND DIAGNOSIS OF INFERTILITY USING TGF$g(b) OR ACTIVIN | LUMINIS PTY. LIMITED (AU) | 2000-08-23 | — | — | EP | disclosed |
| WO-1998039021-A1 | TREATMENT AND DIAGNOSIS OF INFERTILITY USING TGFβ OR ACTIVIN | LUMINIS PTY. LTD. (AU) | 1998-09-11 | — | — | WO | disclosed |
| EP-0347820-B1 | NOVEL SPERGUALIN-RELATED COMPOUNDS AND PREPARATION AND APPLICATION OF THE SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1993-04-21 | — | — | EP | disclosed |
| US-5061787-A | IMMUNOSUPPRESSANTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0241797-B1 | NOVEL SPERGUALIN-RELATED COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4956504-A | IMMUNOMODULATORS, ANTIBIOTICS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1990-09-11 | — | — | US | disclosed |
| EP-0347820-A1 | Novel spergualin-related compounds and preparation and application of the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0309971-A2 | New spergualin-related compound and pharmaceutical composition | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0241797-A2 | Novel spergualin-related compounds and process for producing the same | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1987-10-21 | — | — | EP | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0127108-B1 | PROCESS FOR PREPARING POLYPEPTIDES | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4510083-A | POTASSIUM, CESIUM OR RUBIDIUM CARBONATE BUFFER FOR COUPLING OF AMINO ACID N-CARBOXYANHYDRIDE WITH ANOTHER AMINO ACID OR PEPTIDE | MERCK & CO., INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0127108-A1 | Process for preparing polypeptides | MERCK & CO. INC. (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0127108-A1 | Process for preparing polypeptides | MERCK & CO. INC. (US) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | IL2, IL1A, ILF2 | LTA4H 2615/4885MMP2 2098/4885MMP7 3197/4885 |
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | SERPINB1, DNPEP, PSMB2 | LTA4H 550/4885MMP2 809/4885MMP7 784/4885 |
| US-20230201355-A1 | IL-2 SEQUENCES AND USES THEREOF | IL2, IL2RA, IL4I1 | LTA4H 1086/4885MMP2 1964/4885MMP7 3385/4885 |
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | CCR10, CXCL10, PROKR1 | LTA4H 1225/4885MMP2 2330/4885MMP7 1592/4885 |
| US-20260062478-A1 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | F2RL1, FCGR2A, FCER2 | LTA4H 573/4885MMP2 1186/4885MMP7 1596/4885 |
| US-20240358711-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | CDK4, CDK6, ROS1 | LTA4H 1690/4885MMP2 932/4885MMP7 1726/4885 |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | LTA4H 1285/4885MMP2 1701/4885MMP7 3729/4885 |
| US-12428461-B2 | Treating cancer with a conjugate comprising an IL-2 moiety | IL2, IL2RA, ILF2 | LTA4H 1181/4885MMP2 1634/4885MMP7 3264/4885 |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | TLR3, TLR1, TLR9 | LTA4H 1426/4885MMP2 3316/4885MMP7 2582/4885 |
| US-11879001-B2 | Conjugate comprising an IL-2 moiety | IL2, IL2RA, IL4I1 | LTA4H 1212/4885MMP2 2021/4885MMP7 3797/4885 |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | NOX4, NOX1, NOX5 | LTA4H 847/4885MMP2 1755/4885MMP7 3210/4885 |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | LTA4H 860/4885MMP2 37/4885MMP7 154/4885 |
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | LTA4H 2097/4885MMP2 1551/4885MMP7 883/4885 |
| US-20150004261-A1 | Rhizoma Arisaematis Extracts and Uses Thereof for Wound-Healing Effects | ALKBH1, ALKBH3, ALKBH2 | LTA4H 950/4885MMP2 2327/4885MMP7 788/4885 |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | LTA4H 722/4885MMP2 1752/4885MMP7 1199/4885 |
| US-20220289665-A1 | METHOD FOR PHOTOCLEAVAGE OF AMIDE BONDS | DNPEP, ASPH, ALDH7A1 | LTA4H 704/4885MMP2 764/4885MMP7 3077/4885 |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | LTA4H 374/4885MMP2 2212/4885MMP7 1825/4885 |
| US-20260132136-A1 | Pyrazolo[5,1-f][1,2,4]triazin-4-ones as inhibitors of NOX4 | NOX4, NOX1, NOX3 | LTA4H 946/4885MMP2 2686/4885MMP7 4741/4885 |
| US-20230355815-A1 | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD BRAIN BARRIER | CD209, ARG1, MYADM | LTA4H 698/4885MMP2 2980/4885MMP7 1766/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | LTA4H 2136/4885MMP2 590/4885MMP7 344/4885 |
| US-20260109682-A1 | NOVEL COMPOUNDS AND THE USE FOR PROMOTING HAIR GROWTH OR INHIBITING INFLAMMATORY DISORDERS THEREOF | HSD3B1, HGF, HSD3B2 | LTA4H 594/4885MMP2 886/4885MMP7 319/4885 |
| US-20260035452-A1 | NOVEL INTERLEUKIN-17A (IL-17A)-DERIVED PEPTIDE AND NEUTRALIZING ANTIBODY (AB17-IPL-1) | IL17A, IL2, IL15 | LTA4H 822/4885MMP2 3685/4885MMP7 1407/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | LTA4H 1156/4885MMP2 1740/4885MMP7 1947/4885 |
| US-20230158031-A1 | Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors | BTK, SYK, IRAK2 | LTA4H 964/4885MMP2 2523/4885MMP7 2043/4885 |
| US-20230102309-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | ABL1, ERBB2, ROS1 | LTA4H 3847/4885MMP2 2490/4885MMP7 2903/4885 |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | LTA4H 2097/4885MMP2 1551/4885MMP7 883/4885 |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | LTA4H 639/4885MMP2 626/4885MMP7 647/4885 |
| US-20230174605-A1 | IL-2 SEQUENCES AND USES THEREOF | IL2, IL2RA, IL4I1 | LTA4H 1086/4885MMP2 1964/4885MMP7 3385/4885 |
| US-20220305136-A1 | ANTI-CTLA4 CONJUGATES | CD274, PDCD1LG2, PDCD1 | LTA4H 2590/4885MMP2 2321/4885MMP7 3261/4885 |
| US-11845708-B2 | Method for photocleavage of amide bonds | DNPEP, ASPH, ALDH7A1 | LTA4H 704/4885MMP2 764/4885MMP7 3077/4885 |
| US-20230190723-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | SERPINB1, ELANE, SERPINA2 | LTA4H 398/4885MMP2 263/4885MMP7 78/4885 |
| US-12583929-B2 | Method of treating acute respiratory distress syndrome | CSF3R, CSF1R, FGB | LTA4H 1650/4885MMP2 3673/4885MMP7 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.